nach oben

best practice onkologie

Erschienen in:

26.09.2016 | Karzinoide | Topic

Karzinoide der Lunge

verfasst von: Prof. Dr. E. Stoelben, A. Yordanova, A. Gossmann, M. Hammer-Hellmig, P. Brossart, K. Mayer, M. Essler

Erschienen in: best practice onkologie | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Auszug

Lungenkarzinoide sind seltene Tumoren, die in allen Lebensaltern auftreten. Sie werden in typische (TC) und atypische Karzinoide (AC) unterteilt. Da sie sich häufig in zentraler Lage im Bronchialsystem finden, rufen sie Symptome hervor, die nicht selten fehlgedeutet werden. …

Ambrosini V, Castellucci P, Rubello D et al (2009) 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 30:281–286CrossRefPubMed

Aparicio T, Ducreux M, Baudin E et al (2001) Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 37:1014–1019CrossRefPubMed

Canizares MA, Matilla JM, Cueto A et al (2014) Atypical carcinoid tumours of the lung: prognostic factors and patterns of recurrence. Thorax 69:648–653CrossRefPubMed

Caplin ME, Baudin E, Ferolla P et al (2015) Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol 26:1604–1620CrossRefPubMed

Caplin ME, Pavel M, Cwikla JB et al (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371:224–233CrossRefPubMed

Castellano D, Capdevila J, Sastre J et al (2013) Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of the Spanish Neuroendocrine Tumour Group (GETNE0801). Eur J Cancer 49:3780–3787CrossRefPubMed

Chakravarthy A, Abrams RA (1995) Radiation therapy in the management of patients with malignant carcinoid tumors. Cancer 75:1386–1390CrossRefPubMed

Chong CR, Wirth LJ, Nishino M et al (2014) Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer 86:241–246CrossRefPubMedPubMedCentral

Chowdhury S CP, Spicer Jf, Harper Pg (2006) Carcinoid tumors of the lung. In: Raghavan D (ed) Textbook of uncommon cancer. Wiley, Weinheim, p 307–312CrossRef

10.

Clinical Lung Cancer Genome P, Network Genomic M (2013) A genomics-based classification of human lung tumors. Sci Transl Med 5:209ra153

11.

Crona J, Fanola I, Lindholm DP et al (2013) Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology 98:151–155CrossRefPubMed

12.

Daniels CE, Lowe VJ, Aubry MC et al (2007) The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest 131:255–260CrossRefPubMed

13.

Detterbeck FC (2010) Management of carcinoid tumors. Ann Thorac Surg 89:998–1005CrossRefPubMed

14.

Fernandez-Cuesta L, Peifer M, Lu X et al (2014) Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun 5:3518CrossRefPubMedPubMedCentral

15.

Filosso PL, Guerrera F, Evangelista A et al (2015) Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Group. Eur J Cardiothorac Surg 48:441–447; discussion 447CrossRefPubMed

16.

Filosso PL, Ruffini E, Oliaro A et al (2002) Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg 21:913–917CrossRefPubMed

17.

Forde PM, Hooker CM, Boikos SA et al (2014) Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report. J Thorac Oncol 9:414–418CrossRefPubMedPubMedCentral

18.

Garcia-Yuste M, Matilla JM, Cueto A et al (2007) Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung. Eur J Cardiothorac Surg 31:192–197CrossRefPubMed

19.

Kaifi JT, Kayser G, Ruf J et al (2015) The diagnosis and treatment of bronchopulmonary carcinoid. Dtsch Arztebl Int 112:479–485

20.

Kayani I, Conry BG, Groves AM et al (2009) A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 50:1927–1932CrossRefPubMed

21.

Kulke MH, Lenz HJ, Meropol NJ et al (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403–3410CrossRefPubMed

22.

Mackley HB, Videtic GM (2006) Primary carcinoid tumors of the lung: a role for radiotherapy. Oncology (Williston Park) 20:1537–1543; discussion 1544–1535, 1549

23.

Murthy R, Eng C, Krishnan S et al (2007) Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol 18:1588–1591CrossRefPubMed

24.

Naalsund A, Rostad H, Strom EH et al (2011) Carcinoid lung tumors — incidence, treatment and outcomes: a population-based study. Eur J Cardiothorac Surg 39:565–569CrossRefPubMed

25.

Oberg K, Ferone D, Kaltsas G et al (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy. Neuroendocrinology 90:209–213CrossRefPubMed

26.

Pattenden HA, Leung M, Beddow E et al (2015) Test performance of PET-CT for mediastinal lymph node staging of pulmonary carcinoid tumours. Thorax 70:379–381CrossRefPubMed

27.

Pavel M, Baudin E, Couvelard A et al (2012) ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157–176CrossRefPubMed

28.

Pavel ME, Hainsworth JD, Baudin E et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005–2012CrossRefPubMed

29.

Righi L, Volante M, Tavaglione V et al (2010) Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 ‚clinically aggressive ‘cases. Ann Oncol 21:548–555CrossRefPubMed

30.

Rinke A, Muller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663CrossRefPubMed

31.

Steiner M, Neri D (2011) Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res 17:6406–6416CrossRefPubMed

32.

Stoelben E, Koryllos A, Gossmann A (2013) [The small lung nodule: dealing with a frequent radiological finding]. Zentralbl Chir 138 (Suppl 1):S6–10PubMed

33.

Sun W, Lipsitz S, Catalano P et al (2005) Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23:4897–4904CrossRefPubMed

34.

Travis WD, Brambilla E, Nicholson AG et al (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10:1243–1260CrossRefPubMed

35.

Van Essen M, Krenning EP, De Jong M et al (2007) Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 46:723–734CrossRefPubMed

36.

Venkitaraman B, Karunanithi S, Kumar A et al (2014) Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging 41:856–864CrossRefPubMed

37.

Walter T, Planchard D, Bouledrak K et al (2016) Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors. Lung Cancer 96:68–73CrossRefPubMed

38.

Wittekind C, Meyer Hj (2010) TNM. Klassifikation maligner Tumoren. Wiley, Weinheim

39.

Yao JC, Fazio N, Singh S et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387:968–977CrossRefPubMed

40.

Yao JC, Phan A, Hoff PM et al (2008) Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26:1316–1323CrossRefPubMed

Titel: Karzinoide der Lunge
verfasst von: Prof. Dr. E. Stoelben
A. Yordanova
A. Gossmann
M. Hammer-Hellmig
P. Brossart
K. Mayer
M. Essler
Publikationsdatum: 26.09.2016
Verlag: Springer Berlin Heidelberg
Schlagwörter: Karzinoide
Neuroendokrine Tumoren
Erschienen in: best practice onkologie / Ausgabe 5/2016
Print ISSN: 0946-4565
Elektronische ISSN: 1862-8559
DOI: https://doi.org/10.1007/s11654-016-0586-1

Springer Medizin

Karzinoide der Lunge

Auszug

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Schnelle Anpassungsfähigkeit des Magenkrebserregers Helicobacter pylori ergründet

Rundum gut versorgt

Eine komplexe Nutzen-Risikobilanz

Neu aufgelegt: Prostatakrebs-Ratgeber

Psychoonkologische Beratung über die Landeskrebsgesellschaften in der Deutschen Krebsgesellschaft e.V.

Fachverbände lehnen Zytostatika-Ausschreibung ab

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie